3696 — Insilico Medicine Cayman TopCo Share News
0.000.00%
Last trade - 00:00- HK$22.88bn
- HK$18.44bn
- $56.24m
Press Digest: Financial Times - March 30
Insilico Medicine set for biggest jump in 11 weeks on Eli Lilly deal
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says (updated)
Brief: Insilico Medicine Cayman TopCo Reports 2025 Revenue Of $56.2 Million
Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says
Brief: Eli Lilly To Sign $2 Bln Deal For AI Drug Development With Hong Kong Biotech Insilico Medicine - FT
Brief: Insilico Medicine & Tenacia Biotechnology Expand AI-Driven CNS Collaboration
Brief: Insilico Medicine Cayman Topco Says Co, Tenacia Biotechnology Expand Ai-Driven Cns Collaboration
Insilico Medicine And Aska Pharmaceutical Expand Partnership To Discover Novel Targets For Women's Health
Brief: Insilico Medicine Cayman TopCo Expects FY Loss Attributable Of USD352.1 MLN-USD355.8 MLN
InSilico hits fresh high on partnership deal with China Medical
Insilico hits fresh high on milestone payment from Menarini Group
Insilico jumps on cardiometabolic therapies partnership with Qilu Pharma
Brief: Insilico Medicine Cayman TopCo, Qilu Pharmaceutical Enter Into Drug Development Collaboration Valued At Over HK$931 Mln
Qilu Pharmaceutical in metabolic disease development deal with Insilico Medicine
Brief: Insilico Medicine Receives IND Approval From FDA For ISM8969, An AI-Empowered Potential Best-In-Class NLRP3 Inhibitor
Insilico hits highest since debut on FDA IND approval for Parkinson's treatment
Brief: Insilico Medicine Cayman Topco Receives FDA IND Approval For ISM8969
Brief: Insilico Medicine Cayman TopCo Says Co And Hygtia Enter Collaboration Valued At Over HKD500 Million